Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 13;24(1):90–98. doi: 10.1093/neuonc/noab108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 2 — Survival analysis after BNCT and after HGM diagnosis. (A, B) Kaplan–Meier curves after BNCT and after diagnosis. (A) The mOS after BNCT for the sum of the grade 2 and 3 cases with 95% CI was 29.6 (95% CI: 16.1–40.4) months. The mOS after BNCT for the grade 2 cases was 44.4 (95% CI: 27.4–not determined) months, and that for the grade 3 cases was 21.6 (10.6–30.6) months (P = .0009, log-rank test). (B) The mOS value for the sum of the grade 2 and 3 groups after the diagnosis was 98.4 (95% CI: 68.7–169.4) months. The mOS after diagnosis for the grade 2 group was 224.4 (95% CI: 75.9–325.3) months, and that for the grade 3 group was 69.6 (42.8–120.3) months (P = .0111, log-rank test). Abbreviations: BNCT = boron neutron capture therapy; HGM = high-grade meningioma; mOS = median overall survival.